In addition, adalimumab, the only TNF-α antagonist approved by the FDA and the European Medicines Agency (EMA) for moderate-to-severe HS, highlights mTORC1’s involvement in HS pathogenesis and its potential role on the efficacy of TNF-α inhibition (80). Here, TNF is linked to histiocytic sarcoma.